)
Enovis (ENOV) investor relations material
Enovis M&A announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Deal rationale and strategic fit
Acquisition accelerates entry into surgical robotics, expanding the enabling technology ecosystem and reinforcing a long-term growth strategy in orthopedics and automation.
eCential complements existing platforms, providing planning, navigation, and robotic capabilities for surgeons across care settings, and integrates with ASTRA Portal and ARVIS.
Establishes a Robotics Center of Excellence in Grenoble, France, leveraging a specialized team and local talent pool.
Builds on a pre-existing partnership, validating technical and cultural alignment and a shared innovation roadmap.
Focus is on knee and shoulder applications, leveraging validated technology and proprietary robotic control layers.
Financial terms and conditions
Upfront enterprise value of €155 million (~€176 million cash at closing), plus up to €35 million in milestone payments tied to regulatory and commercial deliverables.
Funded through cash on hand and existing revolving credit facility; leverage increases by about half a turn, expected to return to ~3x by end of 2027.
No revenue contribution expected until 2028; margin dilution of ~150 basis points in 2027, offset by 50 basis points of underlying improvement.
Free cash flow conversion expected to reach 50% in 2027 and 70% in 2029, with at least $100 million in free cash flow targeted for next year.
Synergies and expected cost savings
Integration enables a unified, scalable tech infrastructure and cohesive surgeon experience across platforms.
Commercial teams will benefit from selling and servicing a single technology platform, improving efficiency.
Acquisition supplements engineering with robotics expertise, supporting the creation of a Robotics Center of Excellence.
Accelerates time to market for robotic solutions and enhances development capabilities.
Integration expected to dilute adjusted EBITDA margin by 150 basis points in 2027, partially offset by 50 basis points of underlying improvement.
- Q2 2026 saw 5% organic growth, margin gains, strong cash flow, and reaffirmed guidance.ENOV
Q2 2026 - Double-digit growth, tech innovation, and ASC expansion drive strong outlook for 2026.ENOV
2026 CG Musculoskeletal Conference - All director nominees and proposals were approved by majority, with no stakeholder questions.ENOV
AGM 2026 - Q1 2026 sales up 5%, margins and EPS improved, guidance reaffirmed amid macro headwinds.ENOV
Q1 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.ENOV
Proxy filing - Board recommends all proposals, emphasizing governance, pay-for-performance, and ESG focus.ENOV
Proxy filing - 2025 saw robust sales growth, margin gains, and innovation, with 2026 guidance targeting further improvements.ENOV
Q4 2025 - Q1 2025 sales up 8% with margin gains; revenue outlook raised, EBITDA trimmed on tariffs.ENOV
Q1 2025 - 6%-6.5% organic growth and margin expansion expected in 2025, driven by innovation and integration.ENOV
43rd Annual J.P. Morgan Healthcare Conference 2025
Next Enovis earnings date
Next Enovis earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage